Next, both HCC and CRC patients were stratified into two groups: ADAR1-down and ADAR1-up, based on the decreased or increased expression of ADAR1 in tumors compared to their matched NT samples, respectively (Fig. 6e, f, lower panels). This evidence concerns the gene ADAR and hepatocellular carcinoma.